• Vaccine Name: Recombinant HIV gp120 with adjuvant NanoEmulsion
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0000819
• Type: Subunit vaccine
• Antigen: HIV glycoprotein 120, which has a role in facilitating coreceptor interaction and in mediating virus binding to cellular CD4 (Bielinska et al., 2008).
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001319
  • Description: An oil-in-water nanoemulsion (NE) was used as the mucosal adjuvant for this vaccine (Bielinska et al., 2008).
• Preparation: The gp120 and NE vaccines were prepared by mixing NE with gp120 protein solution, using pyrogen-free saline as a diluent (Bielinska et al., 2008).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were immunized with two or three intranasal administrations of gp120/NE formulation at 3 weeks apart. The immunizations of 10 microliters were performed by slowly applying gp120/NE mixes to the nares.Control mice were immunized with gp120 in saline, with NE alone or saline. Intramuscular immunization was performed with two doses, 3 weeks apart, of 20 micrograms of gp120 injected in 50 microliters of either saline or 1% NE (Bielinska et al., 2008).
• Immune Response: Immunized mice demonstrated robust serum anti-gp120 IgG, as well as bronchial, vaginal, and serum anti-gp120 IgA . The analysis of gp120-specific CTL proliferation, INF- induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).

Guinea pig Response

• Host Strain: Hartley
• Vaccination Protocol: Hartley guinea pigs were immunized intranasally with two administrations (50 microliters per nare) of gp120/NE mix at 3 weeks apart (Bielinska et al., 2008).
• Immune Response: Immunization produced significant levels of serum anti-gp120 IgG antibodies in all animals, as was seen with the mice. The analysis of gp120-specific CTL proliferation, INF gamma induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).